Tislelizumab Combined With Anlotinib And Chemotherapy (SOX) In Neoadjuvant Therapy For Locally Advanced Adenocarcinoma Of Esophagogastric Junction

Conditions: Immunotherapy Gastroesophageal Junction Interventions: Drug: Tislelizumab; Drug: Anlotinib; Drug: Oxaliplatin; Drug: Tegafur Sponsors: Fujian Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials